These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif. Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171 [TBL] [Abstract][Full Text] [Related]
13. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Burton DR; Hessell AJ; Keele BF; Klasse PJ; Ketas TA; Moldt B; Dunlop DC; Poignard P; Doyle LA; Cavacini L; Veazey RS; Moore JP Proc Natl Acad Sci U S A; 2011 Jul; 108(27):11181-6. PubMed ID: 21690411 [TBL] [Abstract][Full Text] [Related]
14. Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs. Bolton DL; Pegu A; Wang K; McGinnis K; Nason M; Foulds K; Letukas V; Schmidt SD; Chen X; Todd JP; Lifson JD; Rao S; Michael NL; Robb ML; Mascola JR; Koup RA J Virol; 2016 Feb; 90(3):1321-32. PubMed ID: 26581981 [TBL] [Abstract][Full Text] [Related]
15. Development of a tier 1 R5 clade C simian-human immunodeficiency virus as a tool to test neutralizing antibody-based immunoprophylaxis. Siddappa NB; Hemashettar G; Wong YL; Lakhashe S; Rasmussen RA; Watkins JD; Novembre FJ; Villinger F; Else JG; Montefiori DC; Ruprecht RM J Med Primatol; 2011 Apr; 40(2):120-8. PubMed ID: 21044092 [TBL] [Abstract][Full Text] [Related]
16. Induction of neutralizing antibodies against tier 2 human immunodeficiency virus 1 in rhesus macaques infected with tier 1B simian/human immunodeficiency virus. Himeno A; Ishida Y; Mori H; Matsuura K; Kikukawa M; Sakawaki H; Miura T Arch Virol; 2019 May; 164(5):1297-1308. PubMed ID: 30820667 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of a multigenic protein vaccine containing multimeric HIV gp160 against heterologous SHIV clade C challenges. Rasmussen RA; Ong H; Song R; Chenine AL; Ayash-Rashkovsky M; Hu SL; Polacino P; Else JG; Novembre FJ; Ruprecht RM; AIDS; 2007 Sep; 21(14):1841-8. PubMed ID: 17721091 [TBL] [Abstract][Full Text] [Related]
18. Vaccine-Induced, High-Magnitude HIV Env-Specific Antibodies with Fc-Mediated Effector Functions Are Insufficient to Protect Infant Rhesus Macaques against Oral SHIV Infection. Curtis AD; Saha PT; Dennis M; Berendam SJ; Ramasubramanian P; Cross KA; Alam SM; Ferrari G; Kozlowski PA; Fouda GG; Hudgens MG; Van Rompay KKA; Pollara J; Permar SR; De Paris K mSphere; 2022 Feb; 7(1):e0083921. PubMed ID: 35196125 [TBL] [Abstract][Full Text] [Related]
19. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. Derby NR; Kraft Z; Kan E; Crooks ET; Barnett SW; Srivastava IK; Binley JM; Stamatatos L J Virol; 2006 Sep; 80(17):8745-62. PubMed ID: 16912322 [TBL] [Abstract][Full Text] [Related]
20. Neutralization-sensitive R5-tropic simian-human immunodeficiency virus SHIV-2873Nip, which carries env isolated from an infant with a recent HIV clade C infection. Siddappa NB; Song R; Kramer VG; Chenine AL; Velu V; Ong H; Rasmussen RA; Grisson RD; Wood C; Zhang H; Kankasa C; Amara RR; Else JG; Novembre FJ; Montefiori DC; Ruprecht RM J Virol; 2009 Feb; 83(3):1422-32. PubMed ID: 19019970 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]